Filing Flows › Co-Diagnostics (CODX) › Q1 2026 › vs Q4 2025
Co-Diagnostics (CODX) Q1 2026 vs Q4 2025 (quarter over quarter)
Co-Diagnostics's revenue fell $118K (-45%) from $264K in Q4 2025 to $146K in Q1 2026.
Co-Diagnostics, Q1 2026: revenue $146K (+190% year over year), net loss $9.1M, operating cash flow −$7.8M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $146K | $264K | −$118K | -45% |
| Other income, net | $69K | $322K | −$253K | -79% |
| Net loss | $9.1M | $25.7M | −$16.6M | -64% |
| Costs & expenses | $9.4M | $26.8M | −$17.5M | -65% |
| Operating costs | $9.4M | $26.8M | −$17.5M | -65% |
| Income tax | $1K | −$474K | $474K | — |
| Research & development | $5.9M | $5.1M | $835K | +16% |
| Sales & marketing | $468K | $545K | −$77K | -14% |
| General & admin | $2.5M | $1.9M | $634K | +34% |
| Other operating costs | $255K | $19.1M | −$18.9M | -99% |
| Operating cash sources | $9.1M | $25.7M | −$16.6M | -64% |
| Depreciation & amortization | $255K | $268K | −$12K | -5% |
| Share-based compensation | $219K | $292K | −$73K | -25% |
| Working capital & other | $819K | $19.0M | −$18.2M | -96% |
| Cash used in operations | $7.8M | $6.2M | $1.6M | +27% |
| Net loss absorbed | $9.1M | $25.7M | −$16.6M | -64% |
Questions
How much did Co-Diagnostics's revenue grow quarter over quarter in Q1 2026?
Co-Diagnostics's revenue fell $118K (-45%) from $264K in Q4 2025 to $146K in Q1 2026.